Prognostic significance of percentage of bronchioloalveolar pattern in adenocarcinomas of the lung.

Bronchioloalveolar (BA) carcinoma of the lung is considered to have a better prognosis than that of common adenocarcinomas of the lung. However, a minor component of the BA pattern is common in many lung adenocarcinomas and the criteria for designating an adenocarcinoma as BA are not well defined. We assessed the clinicopathologic features of 238 cases of lung adenocarcinoma with a partial or predominant BA pattern. Tumors were classified as BA if more than 75% of the tumor had a BA growth pattern. In other words, the tumor grew along pre-existing lung structures without invasion or destruction of parenchyma. Tumors with 50% to 75% BA pattern were considered mixed and tumors with less than 50% BA pattern were designated as solid/acinar (S/A). Fixed, paraffin-embedded tissue sections of each neoplasm were also assessed using immunohistochemical methods with a panel of antibodies specific for p53, retinoblastoma protein, p16, cyclin D1, and cyclin E, and the results were correlated with clinical and pathologic parameters. Our results show that the 5-year survival rate of patients with BA and mixed tumors, 63% and 60%, respectively, was significantly better than that of patients with S/A tumors (P =.026). Patients with BA tumors were more frequently women (55.9%) compared with patients with mixed (48.3%) and S/A (43.8%) tumors. Bronchioloalveolar and mixed tumors were similarly associated with tobacco use, 88.2% and 85%, respectively; slightly less than S/A tumors (93.8%). Clinical and pathologic parameters did not correlate with immunohistochemical results. In conclusion, patients with BA or mixed tumors have similar 5-year survival, better than that of patients with S/A tumors, suggesting that adenocarcinomas can be designated as BA when at least 50% of the tumor has a BA pattern.

[1]  R. Welsh,et al.  Prognostic factors in T1 NO MO adenocarcinomas and bronchioloalveolar carcinomas of the lung. , 1999, American journal of clinical pathology.

[2]  V. Rusch,et al.  p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. , 1994, Chest.

[3]  R. Figlin,et al.  Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer , 1999, Journal of Cancer Research and Clinical Oncology.

[4]  A. Giordano,et al.  Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. , 1999, American journal of respiratory cell and molecular biology.

[5]  J. Minna,et al.  Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  W. Mooi,et al.  The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. , 1996, Lung cancer.

[7]  S. Reed,et al.  Deregulated cyclin E induces chromosome instability , 1999, Nature.

[8]  R. Sutherland,et al.  Cyclins and breast cancer. , 1996, Cancer treatment and research.

[9]  M. Fukuoka,et al.  p53 status and prognosis in stage I-IIIa non-small cell lung cancer. , 1997, International journal of oncology.

[10]  H. Matsuda,et al.  Inversely correlated expression of p16 and Rb protein in non‐small cell lung cancers: An immunohistochemical study , 1996, International journal of cancer.

[11]  J. Farber,et al.  Analysis of cell type and radiographic presentation as predictors of the clinical course of patients with bronchioalveolar cell carcinoma. , 1998, Chest.

[12]  B. Gasser,et al.  Bronchoalveolar carcinoma: histopathologic study of evolution in a series of 105 surgically treated patients. , 1998, Chest.

[13]  S. Kido,et al.  Prognostic value of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma. , 1999, The Annals of thoracic surgery.

[14]  I. Kawase,et al.  Clinical significance of p53 in non-small-cell lung cancer. , 1999, Oncology reports.

[15]  S. Piantadosi,et al.  Recurrence and survival following resection of bronchioloalveolar carcinoma of the lung--The Lung Cancer Study Group experience. , 1989, Annals of surgery.

[16]  S. Jiang,et al.  Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. , 1998, The American journal of pathology.

[17]  A. Patchefsky,et al.  Bronchoalveolar cell carcinoma of the lung. , 1986, The Annals of thoracic surgery.

[18]  P. Pairolero,et al.  Bronchoalveolar carcinoma: factors affecting survival. , 1991, The Annals of thoracic surgery.

[19]  Y. Shimosato,et al.  Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.

[20]  T. Halazonetis,et al.  Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. , 1998, The American journal of pathology.

[21]  K. Sugimachi,et al.  p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  D. Niewoehner,et al.  Do molecular markers predict survival in non-small-cell lung cancer? , 1998, American journal of respiratory and critical care medicine.

[23]  W. Richards,et al.  Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  C. Cordon-Cardo Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. , 1995, The American journal of pathology.

[25]  E. Mark,et al.  Bronchoalveolar carcinoma: clinical, radiologic, and pathologic factors and survival. , 1999, The Journal of thoracic and cardiovascular surgery.

[26]  X. Liu,et al.  G1 control gene status is frequently altered in resectable non‐small cell lung cancer , 1997, International journal of cancer.

[27]  A. Marchetti,et al.  Cyclin D1 and retinoblastoma susceptibility gene alterations in non‐small cell lung cancer , 1998, International journal of cancer.

[28]  D. Sabiston,et al.  Alveolar cell carcinoma of the lung: a retrospective analysis of 205 patients. , 1988, The Annals of thoracic surgery.

[29]  Y. Yatabe,et al.  Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  D. Niewoehner,et al.  Rb and p16INK4a expression in resected non-small cell lung tumors. , 1996, Cancer research.

[31]  Elson Ce,et al.  Morphologic and immunocytochemical studies of bronchioloalveolar carcinoma at Duke University Medical Center, 1968-1986. , 1989 .

[32]  A. Marchetti,et al.  p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. , 1993, Cancer research.

[33]  J. Sørensen,et al.  Prognostic implications of histopathologic subtyping in patients with surgically treated stage I or II adenocarcinoma of the lung. , 1989, The Journal of thoracic and cardiovascular surgery.

[34]  Y. Fujiwara,et al.  Prognostic Significance of p53 and ras Gene Abnormalities in Lung Adenocarcinoma Patients with Stage I Disease after Curative Resection , 1994, Japanese journal of cancer research : Gann.

[35]  J. Lee,et al.  Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Hannon,et al.  Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3). , 1995, Cytogenetics and cell genetics.

[37]  S. Barsky,et al.  Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features , 1994, Cancer.

[38]  S. Rodenhuis,et al.  Comparative analysis of p53 gene mutations and protein accumulation in human non‐small‐cell lung cancer , 1995, International journal of cancer.

[39]  H. Ishida,et al.  The prognostic significance of p53 and bcl‐2 expression in lung adenocarcinoma and its correlation with ki‐67 growth fraction , 1997, Cancer.

[40]  Setsuo Hirohashi,et al.  Small adenocarcinoma of the lung. Histologic characteristics and prognosis , 1995 .

[41]  K. Yasumoto,et al.  Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma , 1997, Cancer.

[42]  G. Jianhua,et al.  A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers. , 1998, Cancer letters.

[43]  J. Izbicki,et al.  Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer. , 1995, The Journal of thoracic and cardiovascular surgery.

[44]  L. Santambrogio,et al.  Prognostic significance of different biomarkers in non-small cell lung cancer. , 1999, Oncology reports.

[45]  J. Paré,et al.  Differentiating bronchioloalveolar carcinoma from adenocarcinoma. , 1982, The American review of respiratory disease.

[46]  W. Benedict,et al.  Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  W. Benedict,et al.  Altered retinoblastoma protein expression in nonsmall cell lung cancer , 1997, Cancer.

[48]  J. Manning,et al.  Bronchioloalveolar carcinoma: The significance of two histopathologic types , 1984, Cancer.